NEW YORK, April 15 (GenomeWeb News) - Stratagene today announced that it has exclusively licensed intellectual property held by the Sidney Kimmel Cancer Center of San Diego.
Under the terms of the agreement, Stratagene will get access to pending patents and related technology developed in the lab of Gennadi Glinsky and used to discover cancer-related genes. Stratagene will obtain exclusive rights to certain gene groups that have been shown to have predictive capabilities for cancer, particularly prostate, and breast cancers.
Financial terms of the agreement were not disclosed.
The company said it would use the IP to develop diagnostic tests based on its quantitative PCR technology.